Empiric vancomycin use in febrile neutropenic oncology patients
- PMID: 25734080
- PMCID: PMC4324182
- DOI: 10.1093/ofid/ofu006
Empiric vancomycin use in febrile neutropenic oncology patients
Abstract
Vancomycin is commonly added as empiric therapy for febrile neutropenia. A retrospective chart review was conducted at a large community teaching institution to evaluate vancomycin use in oncology patients. The results revealed that a majority of empiric vancomycin therapy was inappropriate, raising concern for antibiotic resistance and prompting opportunities for improvement.
Keywords: antibiotics; empiric; febrile neutropenia; oncology; vancomycin.
Similar articles
-
Impact of a clinical pathway on appropriate empiric vancomycin use in cancer patients with febrile neutropenia.J Oncol Pharm Pract. 2017 Dec;23(8):575-581. doi: 10.1177/1078155216668672. Epub 2016 Sep 8. J Oncol Pharm Pract. 2017. PMID: 27609336
-
Evaluation of empiric vancomycin therapy in children with fever and neutropenia.Pharmacotherapy. 1999 Nov;19(11):1315-20. doi: 10.1592/phco.19.16.1315.30867. Pharmacotherapy. 1999. PMID: 10555937
-
Comparison of Empiric Antibiotic Escalation Therapy with Vancomycin (VAN) versus Linezolid (LIN) in Patients with Febrile Neutropenia.Mediterr J Hematol Infect Dis. 2022 May 1;14(1):e2022032. doi: 10.4084/MJHID.2022.032. eCollection 2022. Mediterr J Hematol Infect Dis. 2022. PMID: 35615326 Free PMC article.
-
Evaluation of empiric antibiotic de-escalation in febrile neutropenia.J Oncol Pharm Pract. 2016 Oct;22(5):696-701. doi: 10.1177/1078155215597558. Epub 2015 Jul 30. J Oncol Pharm Pract. 2016. PMID: 26227319 Review.
-
Assessment of Initial Febrile Neutropenia Management in Hospitalized Cancer Patients at a Community Cancer Center.J Adv Pract Oncol. 2018 Sep-Oct;9(6):659-664. Epub 2018 Sep 1. J Adv Pract Oncol. 2018. PMID: 31186987 Free PMC article. Review.
Cited by
-
Causative Organisms and Associated Antimicrobial Resistance in Healthcare-Associated, Central Line-Associated Bloodstream Infections From Oncology Settings, 2009-2012.Clin Infect Dis. 2016 May 15;62(10):1203-9. doi: 10.1093/cid/ciw113. Epub 2016 Mar 1. Clin Infect Dis. 2016. PMID: 26936664 Free PMC article.
-
Contribution of Population Pharmacokinetics of Glycopeptides and Antifungals to Dosage Adaptation in Paediatric Onco-hematological Malignancies: A Review.Front Pharmacol. 2021 Apr 1;12:635345. doi: 10.3389/fphar.2021.635345. eCollection 2021. Front Pharmacol. 2021. PMID: 33867986 Free PMC article. Review.
-
Variation in Clinical Practice and Attitudes on Antibacterial Management of Fever and Neutropenia in Patients With Hematologic Malignancy: A Survey of Cancer Centers Across the United States.Open Forum Infect Dis. 2022 Feb 4;9(3):ofac005. doi: 10.1093/ofid/ofac005. eCollection 2022 Mar. Open Forum Infect Dis. 2022. PMID: 35155714 Free PMC article.
-
Impact of Hepatoblastoma on Infectious Complications Following Pediatric Liver Transplantation.Pediatr Transplant. 2025 Feb;29(1):e70035. doi: 10.1111/petr.70035. Pediatr Transplant. 2025. PMID: 39868651 Free PMC article.
-
Assessment of Initial Vancomycin Dosing in Pediatric Oncology Patients.Children (Basel). 2017 Aug 28;4(9):79. doi: 10.3390/children4090079. Children (Basel). 2017. PMID: 28846665 Free PMC article.
References
-
- Moellering RC., Jr. Vancomycin: a 50-year reassessment. Clin Infect Dis. 2006;42(Suppl 1):S3–4. - PubMed
-
- Paul M, Borok S, Fraser A, et al. Empirical antibiotics against gram-positive infections for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2005;55:436–44. - PubMed
-
- Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:e56–93. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources